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Abstract 
 
Stem cell therapies hold potential to stimulate tendon regeneration and homeostasis, which is 
maintained in response to the native mechanical environment. Activins are members of the 
mechano-responsive TGF-β superfamily that participates in the regulation of several 
downstream biological processes. Mechanosensitive membrane receptors such as activin can 
be activated in different types of stem cells via magnetic nanoparticles (MNPs) through 
remote magnetic actuation resulting in cell differentiation.  
In this work, we target the Activin receptor type IIA (ActRIIA) in human adipose stem cells 
(hASCs), using anti-ActRIIA functionalized MNPs, externally activated through a oscillating 
magnetic bioreactor. Upon activation, the phosphorylation of Smad2/3 is induced allowing 
translocation of the complex to the nucleus, regulating tenogenic transcriptional responses. 
Our study demonstrates the potential remote activation of MNPs tagged hASCs to trigger the 
Activin receptor leading to tenogenic differentiation. These results may provide insights 
toward tendon regeneration therapies. 
 
 
Key words: human adipose derived stem cells; magnetic nanoparticles; Activin A receptor; 
TGF-β/Smad2/3 signaling pathway; tendon tissue engineering 
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Background 
 
 
During tendon development, mechanical forces are transmitted to tendon cells through 
mechanosensitive receptors available in cell membranes.
1, 2
 These changes initiate 
intracellular transduction cascades through the activation and the stimulation of 
transmembrane receptors such as serine/threonine kinase receptors, inducing structural 
changes in the cytoskeleton and promoting regulated transcriptional responses. However, the 
mechano-sensing mechanisms that regulate homeostasis and that are involved in mature 
tendon repair are not well established, hampering the development of successful cell based 
therapies toward tendon regeneration. 
Signaling cascades are the main routes of communication between the membrane and 
intracellular regulatory targets. Among them, TGF-β/Smad2/3 was reported as one of the 
most relevant pathway involved in tenogenic differentiation.
3, 4
 The transforming growth 
factor‑ β (TGF-β) superfamily comprises of the TGFβs, activins, NODAL, bone 
morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and anti-
Müllerian hormone (AMH).
5
 Both TGF-β and mechanical stimulation were found to activate 
the Smad2 and Smad3 molecules, downstream mediators of TGF-β type I (activin receptor-
like kinases, ALKs) and type II receptors, suggesting stress-activated TGF-β signaling drives 
tenogenesis.
6, 7
 ActivinβA has been suggested to activate SMADs pathway8, 9 and to be 
involved in the regulatory pathway of tenomodulin,
10
 a type II transmembrane glycoprotein 
suggested as tendon specific marker.
11, 12
  
Since tendons are notably sensitive to mechanical forces, the use of magnetic mechano-
activation might constitute an effective approach to commit stem cells towards the tenogenic 
lineage through mechanosensing signaling cascades such as TGF-β/Smad2/3 pathway. The 
technology of remote activation of mechanotransduction via magnetic nanoparticles (MNPs) 
has been successfully employed using the MICA Bioreactor (MICA Biosystems Ltd) to 
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deliver the magnetic field to MNPs-tagged cells in both 2D and 3D environments.
13, 14
 MNPs-
tagged cells renders magnetic responsiveness to the engineered systems with potential to be 
remotely controlled and tuned by the actuation of an external magnetic field stimulating cells 
in vitro and upon implantation.
15
 Additionally, the magnetic field was shown to impact 
biological processes
16, 17
 and to render a positive outcome in tissue healing.
18, 19
 Thus, in this 
study we propose to investigate a magnetically actuated TE approach using an externally 
applied oscillating magnetic field over stem cells tenogenic phenotype commitment (Figure 
1). Human adipose-derived stem cells (hASCs) were labelled with MNPs previously 
functionalized with anti-Activin receptor type IIA antibody. The magnetic actuation is 
expected to directly activate the mechanosensitive membrane receptor via functionalized 
MNPs, stimulating hASCs towards controlled cellular responses, more specifically regulating 
the transcription of tenogenic associated genes and driving differentiation. In this way, we can 
compare specific MNPs tagging with non specific effects of an oscilating magnetic field at the 
cell level.  
Previous works using biofunctionalized MNPs targeted to the mechano-responsive ion 
channel TREK1, Wnt Frizzled or PDGFRα and β receptors, have shown the promotion of an 
osteogenic, or smooth muscle cell phenotype, respectively, in hMSCs in vitro and in vivo 
demonstrating the potential for translation as an enabling approach for cell therapies.
13, 14, 20, 21
 
This raised the hypothesis that this approach can be extended to other tissues of the  
musculoskeletal system, such as tendons, where stem cell therapies have already been shown 
to be effective as veterinary treatments and would benefit from further control of 
differentiation.
22
 In this study, we have identified the cell surface receptors which are likely to 
be mechano-magnetically targeted and investigated if we can activate cell signalling pathways 
downstream. 
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Methods 
 
Magnetic nanoparticles (MNPs) conjugation with antibody 
Carboxyl functionalized magnetic nanoparticles (nanomag®-D, 09-02-252, Micromod) were 
covalently coated with Anti-Activin Receptor type IIA (ActRIIA) antibody (ab135634) herein 
termed as “MNPs-ActRIIA“, or with Anti-Rabbit-IgG Fc antibody (ab97196), “MNPs-IgG“, 
by carbodiimide activation as described previously.
14
 Briefly, particles were activated using 
EDAC (03449, Sigma) and NHS (130672, Sigma) dissolved in 0.5 M MES buffer pH6.3 
(Sigma) for 1 h at room temperature under continuous mixing. The particle suspension was 
washed and re-suspended in 0.1 M MES buffer containing 60 μg of anti-rabbit secondary 
antibody (ab97196). The particle suspension was continuously mixed overnight at 4 °C and 
then washed and re-suspended in 0.1 mL MES buffer containing 10 μg of Anti-Activin 
Receptor type IIA antibody. Particle suspensions were mixed for 3h at room temperature and 
then blocked with 25mM Glycine (Sigma) for 30 minutes before final washing and re-
suspension in distilled water. Functionalized nanoparticles were then analyzed for surface 
charge and size using a Zetasizer 3000 HSa (Malvern Instruments). Particles were diluted in 
dH20 and measurements performed at 25 °C. The size and surface charge of ActRIIA-coated 
nanoparticles was compared to IgG-coated nanoparticles. 
 
Cell Isolation and Expansion 
 Human adipose-derived stem cells (hASCs) were obtained from lipoaspirate samples from 
the abdominal region and isolated from surplus tissue samples, under protocols previously 
established with Hospital da Prelada (Porto, Portugal) and with informed consent of the 
patients. The content of the written informed consent and related procedures were reviewed 
and approved by the Hospital Ethics Committee.  
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Human ASCs were isolated from tissue samples and cultured as described before,
23, 24
 and 
have been previously characterized by RT-PCR for CD44, STRO-1, CD105 and CD90 
markers.
23
 Briefly, the tissue was rinsed in phosphate buffered saline (PBS, Sigma-Aldrich) 
containing 10% of an A/A solution. The fat solution was immersed in a 0.05% collagenase 
type II (Sigma/C6885) solution for 45 min at 37 °C under mild agitation. The digested tissue 
was centrifuged at 800 g for 10 min at 4 °C, after which the supernatant was eliminated. Cells 
were expanded in basal medium composed of αMEM (BE12-169F, Lonza) supplemented 
with 10% FBS (10270, Gibco) and 1% A/A  solution (DE17-603E, Lonza). 
 
Phosphorylation assays  
hASCs were seeded at a density of 100,000 cells/well in tissue-culture 6-well plates (Falcon) 
and incubated with carboxyl functionalized MNPs previously coated with anti-ActRIIA 
antibody or with anti-Rabbit-IgG antibody, at 25 µg MNPs/2×10
5
 cells. After a 30 min 
labelling period, in basal serum-free medium, with conjugated MNPs, hASCs were 
incubated/stimulated for 2, 10, or 30 min in basal αMEM medium under magnetic stimulated 
conditions (magnetic field of ≥25 mT from an array of permanent magnets (NdFeB) situated 
beneath the culture plates at a frequency of 1 Hz) with a vertical oscillating magnetic 
bioreactor (MICA Biosystems Ltd) and non-stimulated cells kept in identical conditions in 
incubator. hASCs cultured without MNPs in αMEM medium supplemented with 
Recombinant Human/Mouse/Rat Activin A Protein (338-AC-010, R&D systems) or TGF-β3 
at 10 and 20 ng/mL
25
 were considered positive controls of ActRIIA activation. The dose of 
ligands was chosen based on literature and according to the phospho-Smad2/Smad3 ELISA 
kit. The MNPs conjugated only with secondary IgG antibody constitute the negative control 
of the ActIIRA activation. After each incubation period, cells were analyzed by enzyme-
linked immunosorbent assay (ELISA) that recognizes endogenous levels of phospho-Smad2 
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(Ser465/467) and phospho-Smad3 (Ser423/425) proteins (PathScan® Phospho-Smad2 
(Ser465/467)/Smad3 (Ser423/425) Sandwich ELISA, 12001, Cell Signaling Technology), 
following the manufacturer’s instructions. 
 
 
hASCs culture 
 
hASCs were seeded at 10,000 cells/well in 24-well plates and cultured in the following 
conditions for up to 14 days: i) αMEM medium in static conditions (“ST“), ii) αMEM 
medium in magnetically stimulated conditions (“MICA“), iii) αMEM medium supplemented 
with Activin A (20 ng/mL) in ST, iv) αMEM medium supplemented with Activin A (20 
ng/mL) in MICA, v) αMEM medium in the presence of MNPs-ActRIIA in ST, or vi) αMEM 
medium in the presence of MNPs-ActRIIA in MICA. Medium was changed every 3 days. 
Tenogenic commitment of hASCs was evaluated based on the deposition of tendon 
extracellular matrix (ECM) related proteins and on real time RT-PCR analysis for tendon-
related markers as described in detail below. 
Magnetically  stimulated groups were placed in a commercially available vertical oscillating 
magnetic bioreactor (MICA Biosystems Ltd), providing a magnetic field of ≥25 mT from an 
array of permanent magnets (NdFeB) situated beneath the culture plates at a frequency of 1 
Hz, provided every other day for 1h sessions. Non-stimulated groups were kept in identical 
conditions but without magnetic field. 
 
Dextran Immunolabelling 
Fixed cells labeled with MNPs-ActRIIA or MNPs-IgG undergoing dextran immunolabelling 
were permeabilized with 0.025% Triton-X100 (Sigma/X100)/PBS solution, blocked with 2% 
BSA (A9418, Sigma) in PBS (21-040-CVR, Corning) for 1 h at room temperature and 
incubated overnight with mouse monoclonal anti-Dextran antibody (60026FI.1, Stem Cell 
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technologies) in 0.1% BSA in PBS at 4 °C. Cells were rinsed in PBS, following incubation 
for 1 h at room temperature with anti-mouse IgG FITC antibody (F2012, Sigma). Samples 
were stained with 4,6-Diamidino-2-phenyindole dilactate (DAPI, 40009, VWR) for 10 min 
and Phalloidin Tetramethylrhodamine B isothiocyanate (P1951, Sigma) for 20 min. The 
images were acquired under a Fluorescence Inverted Microscope (Axio Observer, Zeiss). 
mRNA Extraction and Quantitative Polymerase Chain Reaction 
 Total RNA was extracted using TRI reagent (T9424, Sigma) according to the manufacturer’s 
instructions. Briefly, 800 µL of TRI reagent was added to each sample and stored at -80 
o
C. 
After defrosting, samples were incubated with 160 µL of chloroform (Sigma) for 15 min and 
12,000 g centrifuged for 15 min at 4 
o
C. The aqueous fraction was collected and an equal part 
of isopropanol (Sigma Aldrich) was added. After 10 min, samples were centrifuged at 12,000 
g for 10 min at 4 ºC. RNA pellet was washed with 800 μL of 70% ethanol and subsequently 
centrifuged at 7,500 g for 5 min at 4 ºC. Air-dried RNA samples were resuspended in 15 µL 
of RNase/DNase free water (Gibco). RNA quantity and purity were determined with a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). The cDNA synthesis was 
performed with the qScript cDNA Synthesis kit (Quanta Biosciences) and using the 
Mastercycler Realplex (Eppendorf) using an initial amount of total RNA of 1µg in a total 
volume of 20 µL. The quantification of the transcripts was carried out by quantitative 
polymerase chain reaction (qPCR) using the PerfeCTA SYBR Green FastMix kit (Quanta 
Biosciences) following the manufacturer's protocol, in a Real-Time Mastercycler Realplex 
thermocycler (Eppendorf). The primers were pre-designed with PerlPrimer v1.1.21 software 
(Table 1) and synthesized by MWG Biotech. GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) was used as the housekeeping gene. The 2
-ΔΔCt
 method was selected to 
evaluate the relative expression level for each target gene.
26
 All values were first normalized 
against GAPDH values, and then to the hASCs cells collected at day 0.  
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Quantification of Collagen and Non-collagenous Proteins  
The amount of collagen and non-collagenous proteins expressed by hASCs cultured in 2D 
was determined using a semi-quantitative assay, namely Sirius Red/Fast Green Collagen 
Staining Kit (9046, Chondrex). After cells fixation, the dye solution was added and incubated 
for 30 min in order to completely immerse the samples. A dye extraction buffer was then 
mixed and the OD values read in a spectrophotometer (Synergy HT, Biotek Instruments) at 
540 nm and 605 nm. 
 
Immunofluorescence 
Cells were rinsed in PBS and fixed in formalin (INOPAT) prior to the detection of 
Tenomodulin (sc-49324) and Fibromodulin (ab81443) deposition. After cell permeabilization 
with 0.025% Triton-X100 (Sigma/X100)/PBS solution, the blocking step was performed 
using RTU Normal Horse Serum (RTU Vectastain Kit, PK-7200, Vector). Then, cells were 
incubated overnight with anti-tenomodulin and anti-fibromodulin antibodies, diluted in 
antibody diluent with background reducing components from Dako (S3022, Dako) at 4 °C. 
Samples were then rinsed in 0.025% Triton-X100 (Sigma/X100)/PBS solution followed by  
incubation for 1h at room temperature with the respective Alexa fluor 488 (Alfagene) 
considering the host species of the primary antibodies. Samples were stained with 4,6-
Diamidino-2-phenyindole, dilactate (DAPI, 5 μg/μL, D9564, Sigma) for 10 min and with 
Phalloidin–Tetramethylrhodamine B isothiocyanate (P1951, Sigma) for 20 min. Samples 
were observed with a Fluorescence Inverted Microscope (Axio Observer, Zeiss).  
 
Statistics 
Quantitative results are expressed as the mean  standard deviation. Two-Way ANOVA 
followed by Bonferroni’s Multiple Comparison test was assessed to determine whether 
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differences between sample groups were significant, unless specified. Differences were 
considered significant when the P value was < 0.05.  
 
 
Results 
 
Assessment of Smad2/Smad3 phosphorylation in hASCs triggered by TGF-β-like ligands 
TGF-β-like ligands, Activin A and TGF-β3 known for their functions in tendon 
development,
10, 27
 were investigated as inducers of serine/threonine receptor‘s activation and 
consequent phosphorylation of Smad2/3 (Figure 2 A). Using two different ligand doses (10 
and 20 ng/mL) and at varying temporal exposures, Smad2/3 signaling and subsequent gene 
expression has been assessed. Moreover, Activin A and TGF-β3 ligand-receptor binding will 
serve as a positive experimental control of the activation of ActRIIA receptor mediated by 
MNPs-antibody complexes. We investigated the levels of pSmad2/3 following 2, 10, 30 and 
60 min of treatment. The detection of pSmad2/3 proteins was rapid (at 10 min) and 
significantly more intense in Activin A supplemented medium at 20 ng/mL than in medium 
supplemented with TGF-β3 ligand (Figure 2 B). 
 
Development and characterization of functionalized MNPs complexes  
After antibody functionalization by carbodiimide activation (Figure 3 A), the size and surface 
charge of MNPs-ActRIIA and MNPs-IgG were characterized. The particle size increased after 
IgG coating of MNPs in comparison to MNPs coated with anti-ActRIIA (MNPs-ActRIIA). 
Conversely, the surface charge increased in MNPs-ActRIIA (Figure 3 B).  
In order to co-localize functionalized MNPs within hASCs, MNPs-ActRIIA or MNPs-IgG 
labelled cells were visualized by fluorescence microscopy after immuno-labelling the MNPs 
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dextran shell with an anti-dextran antibody (Figure 4), suggesting that 30 min after labelling, 
there is a clear association of MNPs-ActRIIA and MNPs-IgG with cells.  
 
Triggering Smad2/Smad3 phosphorylation in hASCs by MNPs complexes 
The activin receptor activation was indirectly assessed through detection of downstream 
phosphorylation of Smad2/3 using an ELISA kit assay that recognizes endogenous levels of 
these proteins. Magneto-mechanical stimulated groups showed significantly higher 
phosphorylation levels in relation to non-stimulated and to Activin A control groups after 2 
and 10 min, decreasing after 30 min (Figure 5 A) in MNPs-ActRIIA ST and MNPs-ActRIIA 
MICA conditions. The detection of phospho-Smad2/3 proteins seems to be more intense after 
10min in hASCs labeled with MNPs-ActRIIA under magnetic stimulation, which highlights a 
more efficient ActRIIA activation. Results also show a significant elevation of absorbance 
values in comparison to the negative control group, MNPs-IgG, or to the positive control 
group, Activin (Figure 5 B).  
 
 
Triggering tenogenesis in hASCs using MNPs-ActRIIA complex 
In this study, real time RT-PCR analysis, the production assessment of collagen and non-
collagenous proteins and the deposition of Tenomodulin (TNMD) and Fibromodulin (FMOD) 
tendon-related proteins were conducted up to 14 days upon ActRIIA activation under 
magnetic field stimulation provided by MICA bioreactor. 
 
Gene expression analysis 
The expression of tendon associated genes was found to be higher in hASCs bound with 
MNPs-ActRIIA with and without the magnetic stimulation after 7 days  (Figure 6). PCR 
results evidence higher gene expression values in MNPs-ActRIIA after 7 days under magnetic 
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stimulation. Targeted mechano-activation of the ActRIIA using magnetic actuation of MNPs 
attached to the membrane receptor resulted in enhanced upregulation of tenogenic genes, 
TNC, TNMD, SCXA, DCN, and COL3A1 but not COL1A1. Interestingly, MNPs-ActRIIA 
binding alone enhanced TNC expression but not other tenogenic genes, as for example TNC 
gene expression is significantly higher in MNPs-ActRIIA ST (P<0.05) in comparison to 
Activin A ST and to αMEM ST (P<0.01).  
 
 
Extracellular matrix formation assessment  
Of the tendon dry weight, 60% is collagen type I arranged in tensile-resistant fibers
28
 and 
other types such as collagen types III (0-10%), IV (~2%), V, and VI. The non-collagenous 
matrix is primarily made up of glycoproteins which include the proteoglycans such as decorin 
(DCN), tenascin C (TNC), fibromudulin (FMOD) and tenomodulin (TNMD).
29
 ECM 
formation was assessed by production of collagen and non-collagenous proteins as depicted in 
Figure 7. Collagen and non-collagenous proteins production by hASCs significantly increased 
with time in culture from day 0 to 7 days and from 0 to 14 days, respectively (statistical 
significant groups: a and b). Interestingly, the collagen values obtained in MNPs-ActRIIA 
MICA condition were significantly higher than in static conditions after 14 days. These values 
were also higher than  αMEM or Activin A controls. The same trend was observed in non-
collagenous protein production.  
 
Tendon specific markers assessement  
FMOD is highly expressed in the tendon and identified as a critical component of the tendon 
stem cell niche.
30
 The immunodetection of TNMD and FMOD is presented in Figures 8A and 
8B, respectively. Tendon-specific transcription factors such as SCX
3
 are essential and 
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involved in mechanoresponsive tenogenesis through regulation of its downstream ECM 
proteins such as the tendon marker TNMD
31, 32
 and proteoglycans such as FMOD. 
Tenomodulin and Fibromodulin proteins deposition was increased by hASCs previously 
labeled with MNPs-ActRIIA in comparison with hASCs cultured in basal αMEM or in 
αMEM supplemented with Activin A (negative and positive controls, respectively). Also, the 
detection of these proteins after 7 and 14 days of culture was higher when the oscillating 
magnetic field, provided by MICA bioreactor, was applied. 
 
Discussion 
Signal transduction molecules of the Smad family are components of a critical intracellular 
pathway that transmit signals mediated by transmembrane serine/threonine kinase type II 
receptors into the nucleus. Smad2/3 signaling pathways are associated with tendon 
development and transcriptional responses and, to date and to authors knowledge, no 
published studies have reported to locally target and activate Activin receptors upon 
mechano-magnetic stimulation, in order to modulate Smad2/3 signaling. Binding of TGF-β 
family ligands, such as Activins or TGF-β3, to receptors, leads to the recruitment, 
phosphorylation and activation of type I Activin receptor (ALK4), which provides a binding 
site for the downstream substrates, initiating the intracellular signaling through activation of 
Smad proteins.
33
 In the present work, the assessment of Smad2/Smad3 phosphorylation in 
hASCs triggered by TGF-β-like ligands, showed increased absorbance values in Activin A 
supplemented medium (20 ng/mL) after 10 min, what suggests a more effective 
phosphorylation of Smad proteins. Therefore, Activin A at this concentration was selected as 
the positive control for ActRIIA activation in the subsequent experiments of this study. 
Indeed, the activation of the ligand-receptor complex is described as a relatively fast step in 
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the TGF-β signal transduction, occurring within 2 min after ligand stimulation, and the signal 
is relayed to the activation of Smad proteins, which reach at maximal levels in up to 30-60 
minutes.
34
 
In order to remotely stimulate ActRIIA receptor in a controlled way, MNPs complexes were 
developed and characterized. The results of size and surface charge of the developed 
complexes (MNPs-ActRIIA and MNPs-IgG) suggested improved electrostatic interactions of 
the MNPs coated with anti-ActRIIA with the negatively charged cell membrane, which were 
further co-localized in hASCs after the 30 min period of labelling by immunocytochemistry. 
To understand the capability of functionalized MNPs (MNPs-ActRIIA) to directly target and 
remotely activate the Activin receptor via magneto-mechanical stimulation, we investigated 
the phosphorylation of Smad2/3 using MICA bioreactor and comparing to static environment. 
The outcomes suggested that ActRIIA is a mechanosensitive receptor that can be remotely 
activated using Ab coated MNPs, whose action is favored by the actuation of an external 
magnetic field provided by MICA bioreactor. Previous works using biofunctionalized MNPs 
targeted to mechano-responsive receptors demonstrated an enhanced mechanoactivation of 
the targeted receptors caused by movement of the MNPs-Ab complex in the magnetic field.
14, 
21, 35
 Furthermore, the commitment of hASCs towards tenogenesis using the MNPs-ActRIIA 
complex was studied. Tenoblasts maturation to tenocytes is characterized by the formation of 
enriched ECM and controlled by key tenogenic transcription factors, such as SCX.
36
 The 
TGF-β signaling pathway regulates a diverse group of cellular behaviors such as proliferation, 
differentiation, and growth arrest
37
 and has also been suggested as the most active pathway in 
tendon cells during mouse limb development.
38
 Overall, magnetic actuation of MNPs coated 
with ActRIIA bound to the receptor enhanced the expression of all tendon related genes 
studied. Havis et al. reported that blocking the TGF-β pathway with SB43 inhibitor, 
significantly downregulated SCX and COL1a1, among other gene expression
38
 concluding 
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that TGF-β is required via the Smad2/3 intracellular pathway for expression of tendon-related 
markers in mouse forelimbs.
38
 We can infer that MNPs-ActRIIA and magnetic actuation 
synergistically influenced Smad2/3 mediators. This agrees with other studies using alternate 
mechanical activation methods where phosphorylation assays, and SCX and TNMD 
transcriptional activity was upregulated in response to strain.
12, 31, 39
 Furthermore, the 
fluctuations in gene expression from 7 to 14 days (Figure S1) may be related with ligand 
depletion from the environment causing cells to lose the stimulation and shut down the 
phosphorylation of Smad2, which can occur within a few hours post stimulation.
40, 41
 Dosage 
and stimulation time of TGF-β-like ligands have effects on Smad signaling and short-term 
ligand pulse stimulation results in transient pSmad2, whereas serial pulses or continuous 
stimulation results in sustained pSmad2.
40
 Moreover, there is a time-delay for reaching the 
maximum pSmad2/3 phosphorylation, which we determined to be 10 min after treatment with 
MNPs-ActRIIA or with Activin A supplementation at 20 ng/mL, and nuclear accumulation 
and subsequent regulation of transcriptional responses. Considering these two assertions and 
the results of gene expression we can infer that as the complex MNPs-ActRIIA was provided 
to hASCs once at the beggining of culture, the transcriptional responses observed were time-
dependent and transient mostly affecting gene expression in early culture periods.  
Additionally, the synthesis of a complex matrix of collagen and non-collagenous proteins also 
supports the activation of activin receptor by MNPs-ActRIIA complex under magnetic 
actuation in a more efficient way than using the Activin A ligand to trigger hASCs response. 
Considering the role of TNMD as specific tendon marker and FMOD as a crucial 
proteoglycan component of tendons that regulate physiological ECM assembly, it was 
assessed the deposition of these markers by hASCs tagged MNPs-ActRIIA. Tenomodulin has 
been sugested to be expressed upon Activin II receptor stimulation by myostatin, triggering 
the Smad2/3 signaling cascade and increasing the expression of SCX that ultimately results in 
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the TNMD gene expression.
10
 Thus, upon MICA stimulation, MNPs-ActRIIA complexes are 
likely to act over Activin II receptor, activating the signaling cascade and ultimately inducing 
the transcription of TNMD and its translation into protein. Moreover, FMOD was suggested to 
play a role in the formation of ECM and to regulate TGF-β levels.42 Also, mutations in the 
small leucine-rich proteoglycan gene FMOD result in irregularities in the diameter of collagen 
fibers in the tendons.
43
 Herein, the higher deposition of TNMD and FMOD together with 
Sirius Red/Fast Green Collagen staining assay and RT-PCR, confirms the hypothesis of 
magnetically actuated MNPs-tagged hASCs towards a tenogenic commitment. Moreover, it 
was clear in the present work that the induction of Smad2/3 signaling elicited hASCs 
tenogenic response. However, it is known that other variables outside the target cell determine 
the extent of stimulation by TGF-β cytokines.44 Thus, future studies will take into account the 
impact of extracellular regulators in Smad signaling dynamics, such as ligand exposure, or the 
effect of antagonistic ligands.  
Collectively, the present work has shown that the remote activation of MNPs tagging 
mechanosensitive receptors of hASCs may have potential for controlling stem cell 
differentiation envisioning successful cell therapies for tendon regeneration. Previously, we 
have shown the potential benefit of this apporach in orthopaedic bone tissue engineering and 
similar strategies could be employed for tendon regeneration.
13
 It has been demonstrated that 
magnetic MNPs tagging can be utilised in tendon lineage comitment via ActRIIA/Smad2/3 
signaling cascade, as shown by phosphorylation of Smad2/3 proteins in MNPs-ActRIIA 
tagged hASCs. Further investigation is required to fully explore the mechanism behind signal 
activation and downstream signaling events in response to MNPs-ActRIIA stimulation and 
the effects on hASCs fate and differentiation. The development of this technology raises the 
possibility of remotely controlling TGF-β/Smad2/3 signaling and consequently the control of 
stem cell behavior. Overall, the remote activation of MNPs tagged hASCs may have potential 
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for controlling stem cell differentiation following cell therapy and modulation of signaling 
pathways involved in tendon regeneration. 
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Figure Legends 
Figure 1. Schematic representation of cellular Activin A receptor targeting with MNPs 
functionalized with Anti-Activin type IIA antibody (MNPs-ActRIIA) for tenogenic 
differentiation. 
Figure 2. Phosphorylation assessment of Smad2/Smad3 in hASCs triggered by TGF-β-like 
ligands. A) Schematic of the experimental design for the phosphorylation assay. Treatment of 
hASCs with Activin A and TGF-β3 ligands for up to 60min and subsequent phospho-
Smad2/Smad3 (pSmad2/3) detection; B) Assessment of pSmad2/3 by ELISA kit assay, in 
hASCs cultured in αMEM medium  (cells untreated) or cultured in αMEM medium 
suplemented with Activin A or TGF-β3 at 10 and 20 ng/mL for 10, 30 and 60min. Values 
represent the mean ± SD. Symbol *, **,  *** and **** denotes study groups with statistical 
significant difference P<0.05, P<0.01, P<0.001 and P<0.0001 respectively. 
Figure 3. Development and characterization of functionalized MNPs complexes. A) 
Schematic representation of MNPs functionalization with anti-activin receptor type IIA 
antibody by carbodiimide activation; B) Size and zeta potential analysis of MNPs 
functionalized with anti-activin receptor type IIA antibody (MNPs-ActRIIA) or with IgG 
secondary antibody (MNPs-IgG); C) Dextran (green) immunofluorescence images of hASCs 
labelled with MNPs-ActRIIA or MNPs-IgG. Cell nuclei are shown by DAPI (blue) and the 
cytoskeleton by phalloidin (red). Insets represent lower magnification images. 
Figure 4. Dextran (green) immunofluorescence images of a) hASCs labelled with MNPs-
ActRIIA or MNPs-IgG. Cell nuclei are shown by DAPI (blue) and the cytoskeleton by 
phalloidin (red); b) lower magnification images. 
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Figure 5. Phosphorylation assessment of Smad2/Smad3 in hASCs. A) Phospho-
Smad2/Smad3 ELISA assay of hASCs cultured in Activin A (positive control) and with 
MNPs-ActRIIA under static (ST) or under actuation of a vertically oscillating magnetic field 
(MICA) for 2, 10, and 30min; B) Phospho-Smad2/Smad3 ELISA assay of hASCs cultured 
with MNPs-ActRIIA or MNPs-IgG under static (ST) or under actuation of a vertically 
oscillating magnetic field (MICA) for up to 10min; Values represent the mean ± SD. Symbol 
*, **, *** and **** denotes study groups with statistical significant difference P<0.05, 
P<0.01, P<0.001 and P<0.0001 respectively. 
Figure 6. Real time RT-PCR analysis of tenascin C (TNC), tenomodulin (TNMD), scleraxis 
(SCXA), decorin (DCN), collagen type I (COL1A1) and collagen type III (COL3A1) gene 
expression of hASCs cultured for 7 days in αMEM medium, αMEM supplemented with 
Activin A (20 ng/mL) or labeled with MNPs-ActRIIA in αMEM medium, under static (ST) or 
under actuation of a vertically oscillating magnetic field (MICA). Values represent the mean 
± SD. Symbol * and ** denotes study groups with statistical significant difference P<0.05 and 
P<0.01, P<0.001, by one-way ANOVA. 
Figure 7. Quantification of collagen and non-collagenous proteins by Sirius Red/Fast Green 
Collagen staining kit in hASCs labeled with MNPs-ActRIIA in αMEM medium, under static 
(ST) or under actuation of a vertically oscillating magnetic field (MICA). hASCs cultured for 
up to 14 days in αMEM medium and in αMEM supplemented with Activin A (20 ng/mL) 
were considered the negative and positive experimental controls, respectively. Values 
represent the mean ± SD. Symbol *, **, *** and **** denotes study groups with statistical 
significant difference P<0.05, P<0.01, P<0.001 and P<0.0001 respectively; a and b letters 
represent statistically different groups. 
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Figure 8. Immunocytochemistry of A) Tenomodulin and of B) Fibromodulin proteins (green) 
deposited by hASCs labeled with MNPs-ActRIIA in αMEM medium, under static (ST) or 
under actuation of a vertically oscillating magnetic field (MICA). hASCs cultured for up to 14 
days in αMEM medium and in αMEM supplemented with Activin A (20 ng/mL) were 
considered the negative and positive experimental controls, respectively. DAPI (blue) stains 
cell nuclei. Insets represent hASCs labeled with MNPs-ActRIIA in αMEM medium at day 0. 
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Table 1. Primers used for quantitative RT-PCR analysis. 
Gene Sequence NCBI reference 
Human 
Glyceraldehyde
-3-phosphate 
dehydrogenase 
(GAPDH) 
F- GGGAGCCAAAAGGGTCATCA 
R- GCATGGACTGTGGTCATGAGT 
NM_001256799.1 
Collagen, Type 
I, alpha 1 
(COL1A1) 
F- CCCCAGCCACAAAGAGTCTAC 
R- TTGGTGGGATGTCTTCGTCT 
NM_000088.3 
Collagen, Type 
III, alpha 1 
(COL3A1) 
F- CCTGAAGCTGATGGGGTCAA 
R- CAGTGTGTTTCGTGCAACCAT 
NM_000090.3 
Tenascin C 
(TNC) 
F- ACTGCCAAGTTCACAACAGACC 
R- CCCACAATGACTTCCTTGACTG 
NM_002160.3 
Scleraxis 
(SCXA) 
F- AGAACACCCAGCCCAAACAGAT 
R- TCGCGGTCCTTGCTCAACTTT 
NM_001080514.2 
Decorin (DCN) F- CTAGTCACAGAGCAGCACCTAC 
R- CCAGGGAACCTTTTAATCCGGGAA 
NM_001920.4 
Tenomodulin 
(TNMD) 
F- CCGCGTCTGTGAACCTTTAC 
R- CACCCACCAGTTACAAGGCA 
NM_022144.2 
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Graphical Abstract: Text 
 
Schematic illustration of the process of hASCs-MNPs-ActRIIA labeling and stimulation with 
magnetic field to target the Activin A receptor, initiating the intracellular signaling through 
activation of TGF-β/Smad2/3 towards tenogenesis. The activation of the ligand-receptor 
complex via magneto-mechanical stimulation was confirmed by the assessment of Smad2/3 
phosphorylation in hASCs. Moreover, the remote activation of MNPs tagged hASCs resulted 
in improved collagenous enriched matrix and tenogenic commitment of hASCs, 
demonstrating potential for the modulation of signaling pathways involved in tendon 
regeneration. 
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